Biopharmaceutical Company Submits SMA-Targeted Apitegromab for FDA Biologics License Scholar Rock, a Cambridge, Massachusetts-based late-stage biopharmaceutical company, has submitted a Biologics License Application to the U.S. Food & Drug Administration (FDA) for apitegromab, described as “a muscle-targeted therapy designed and developed to provide clinically meaningful improvement in motor function for people living with SMA [spinal…
Briefly: SMA Drug Submitted to FDA for Biologics License; Study Shows that Somatosensory Stimulation Can Affect Hand Choice
Commentary: Seniors with CVA Also Deserve the Best Outcomes
A new partnership between the World Stroke Organization and Royal Philips calls for a revolution in stroke care. I hope that includes wheeled mobility.
Royal Philips and the World Stroke Organization (WSO) recently announced they are partnering to advocate for better care for patients who experience cerebrovascular accidents (CVA), also known as stroke. Philips’s paper, Time for a Revolution in Stroke Care, noted that CVA “is a leading cause of disability and the second-leading cause of death worldwide. The…
Philips, World Stroke Organization Urge Better Access to CVA Care
The technology to lessen the impact of cerebrovascular accidents isn’t always accessible.
Royal Philips and the World Stroke Organization (WSO) are partnering to bring greater awareness to the need for best-practice care for patients with cerebrovascular accident (CVA), commonly known as stroke. In a Sept. 10 news announcement, Philips said it is “Time for a revolution in stroke care,” referencing a new policy paper co-published with the…